KCS

In the cancer stem cells (CSCs) model, only a small proportion of tumor cells are able to self-renew extensively, while the bulk of cells proceed to differentiate into committed heterogeneous clones. On the basis of the involvement of CSCs in tumourigenesis and treatment resistance, it is conceivable that only eradication of CSCs can lead to a cancer cure. CD133, also known as prominin-1 (PROM-1), is a 5-transmembrane glycoprotein with several isoforms of unknown physiological or pathological function. CD133+ cells was firstly identified as a cancer initiating cell in brain tumor and contributor to the CSC population. Therefore, CD133 are an important target candidate for prevention of relapse and disease progression in brain tumor. In the previous study, we screened the peptide which have higher binding potency to target protein in vitro. To further characterization of found peptides, we investigate the binding properties on cellular level. In addition with this, the peptide conjugated to Gold nanoparticle for novel diagnostic approach.